GNLX:NASDAQ
Genelux Corp
2,50 US$
arrow_downward
-0,79%(-0,020) 1 d
8 oct, 16:00:01 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de GNLX...
Abrir
2,47 US$
Alto
2,53 US$
Bajo
2,42 US$
Cap. burs.
113,11 M
Vol. medio
276,81 mil
Volumen
0,00
Máximo en 52 sem.
8,54 US$
Mínimo en 52 sem.
2,29 US$
BPA
-0,87 US$
Beta
0,59
Acciones en circulación
45,24 M
N.º de empleados
26
Abrir
2,47 US$
Alto
2,53 US$
Bajo
2,42 US$
Cap. burs.
113,11 M
Vol. medio
276,81 mil
Volumen
0,00
Máximo en 52 sem.
8,54 US$
Mínimo en 52 sem.
2,29 US$
BPA
-0,87 US$
Beta
0,59
Acciones en circulación
45,24 M
N.º de empleados
26
Noticias
De fuentes web y partners de noticias
https://www.dars.gov.et/
·
hace 6 días
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Force Index
Perfil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Acerca de Genelux Corp
CEO-
Empleados26
Fundación2001
SedeWestlake Village, California, Estados Unidos
Sector-
Sitio webgenelux.com